An MK-677 (ibutamoren) and ipamorelin “stack” combines two compounds intended to influence growth-hormone signaling, but the supplied human evidence does not evaluate the combination. MK-677 has been studied in randomized trials for specific conditions; that does not establish that combining it with ipamorelin is effective or safe. The supplied sources do not include an FDA approval document for MK-677 or ipamorelin, and clinical studies do not themselves establish FDA approval. 1 2 A clinician should assess goals, medications, and risks.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What is an MK-677 and ipamorelin stack?
An MK-677 and ipamorelin stack is an online term for using two compounds together because each is discussed in relation to growth-hormone signaling. The key fact is that no supplied human study tests the combination, so there is no direct human evidence to show its benefits, side effects, or contraindications as a pair.
MK-677 is another name used for ibutamoren mesylate, an oral growth hormone secretagogue studied in human randomized trials. 1 Ipamorelin is often grouped with growth-hormone secretagogues in online discussions, but the supplied evidence set does not provide a human trial that establishes what ipamorelin does alone or when combined with MK-677.
The evidence gap: no listed human study evaluates this combination
The available MK-677 studies are studies of MK-677, not of a two-compound stack. The randomized hip-fracture study, the Alzheimer disease study, and the diet-induced catabolism study do not evaluate ipamorelin alongside MK-677. 1 2 3 Evidence for one compound cannot establish the efficacy or safety of a combination.
How do MK-677 and ipamorelin affect growth-hormone signaling?
Growth hormone is a hormone made by the pituitary gland. IGF-1 is one downstream signal often measured in growth-hormone research. MK-677 is described as an oral growth hormone secretagogue, while the supplied materials do not provide enough human evidence to make a matching clinical conclusion about ipamorelin. 1
MK-677 (ibutamoren): an oral growth hormone secretagogue studied in humans
The 1998 randomized trial by Murphy and colleagues identifies MK-677 as an orally active growth hormone secretagogue and studied it in diet-induced catabolism. 1 Later randomized research included a multicenter phase IIb study in people recovering from hip fracture and a randomized trial in Alzheimer disease. 2 3 These are meaningful examples of human research, but they do not validate online stack claims.
Ipamorelin: what can and cannot be concluded from the supplied evidence
For ipamorelin, the honest answer is narrow: the supplied evidence set does not include a human randomized trial, observational study, or official label that can support a clinical benefit, side-effect profile, or combination claim. That absence does not prove that a result is impossible. It means a reliable conclusion cannot be drawn from the evidence provided here.
If you are sorting through online claims, our guide to ipamorelin evidence and access questions explains why the strength of the evidence matters more than a product label or a forum protocol.
What benefits are claimed for this stack, and what has actually been studied?
Claims about lean body mass, recovery, sleep, and longevity go beyond what the supplied combination evidence can support. No human stack trial is supplied, and no biomarker result can stand in for a proven patient-important outcome.
Lean mass, body composition, and functional outcomes
ClinicalTrials.gov lists a completed 72-participant study of an oral growth hormone secretagogue in older adults that examined body composition and functional ability. 5 A registry record describes the study question and status; it does not, by itself, establish that a benefit occurred. A separate chronic kidney disease study intended to examine lean body mass was withdrawn. 6
The hip-fracture trial shows that MK-677 was studied in a recovery setting, but its title alone does not establish a general recovery benefit or support adding ipamorelin. 2 Individual results vary, and study findings in one population should not be assumed to apply to another.
Recovery, sleep, and longevity claims
The supplied sources do not establish that the MK-677 and ipamorelin combination improves sleep, speeds recovery, or extends human life. The Alzheimer disease randomized trial specifically reported no clinical effect on disease progression from MK-677. 3 That result does not answer every research question about MK-677, but it is an important reminder that changing a hormone pathway is not the same as creating a meaningful clinical outcome.
Why changes in growth hormone or IGF-1 are not proof of a patient-important benefit
IGF-1 is a biomarker, not an outcome patients can feel or function with. A completed registry study evaluated MK-0677’s effect on IGF-1 levels in 49 people with end-stage renal disease. 4 Even if a biomarker changes, separate research is needed to show whether that change improves strength, mobility, symptoms, quality of life, recovery, or survival.
Is it safe to combine MK-677 and ipamorelin?
The evidence-based answer is that safety of the two-compound combination is unknown from the supplied human evidence. No listed trial evaluates MK-677 plus ipamorelin, so side effects, drug interactions, and contraindications cannot be assumed from research on either compound alone.
Why combination safety cannot be assumed from single-compound research
When two compounds are used together, their effects may differ from either one used alone. The supplied MK-677 trials do not supply combination-safety data with ipamorelin. 1 2 3 This is why a stack should not be treated as a proven protocol simply because each name appears in online peptide discussions.
Questions a licensed clinician may consider before evaluating peptide treatment
- Your health history, current symptoms, and treatment goals.
- Current prescription drugs, supplements, and possible interaction concerns.
- Whether a measurable, patient-important goal is realistic based on the available evidence.
- Whether the product source is licensed and whether a clinician can provide follow-up.
- Whether there is enough evidence to justify exposure to an untested combination.
How does MK-677 compare with ipamorelin and sermorelin?
MK-677 has human randomized studies in the supplied evidence set. The supplied evidence does not provide equivalent direct evidence for ipamorelin or sermorelin, and it does not provide a head-to-head comparison among the three. That makes confident “best” or equivalence claims inappropriate.
| Compound | Mechanism category discussed | Human evidence in supplied sources | Key evidence limit |
|---|---|---|---|
| MK-677 / ibutamoren mesylate | Oral growth hormone secretagogue 1 | Randomized trials in specific populations 1 2 3 | No supplied study tests it with ipamorelin. |
| Ipamorelin | Discussed online as a growth-hormone-related peptide | No direct human study is supplied for this article | Benefits, adverse effects, and combination safety cannot be concluded here. |
| Sermorelin | Included for comparison because it is often discussed in the same category | No direct comparative source is supplied for this article | No supplied head-to-head study with MK-677 or ipamorelin. |
For a broader evidence-focused comparison, see sermorelin, ipamorelin, tesamorelin, and CJC-1295. It is also worth separating a comparison article from individualized care: a chart cannot determine whether any peptide approach fits your health history.
What are safer questions to ask before buying peptides online?
A safer approach starts with source quality and clinical oversight, not a stack recipe. A licensed clinician can review your health history before any prescription decision, while an online product page generally cannot.
Ask what evidence exists for the exact compound, route, population, and combination you are considering. Ask whether the seller provides a legitimate prescription pathway and whether there is follow-up for questions or side effects. “Research-use” language is not evidence that a product is appropriate for self-treatment.
Our guide to finding a legitimate peptide source and explanation of research-only versus prescription access can help you assess online claims more carefully. No compounded MK-677 or ipamorelin treatment is listed in Chia’s current offerings.
What is the bottom line on the MK-677 and ipamorelin stack?
The bottom line is simple: the combination has no supplied human trial evidence, even though MK-677 alone has been studied in randomized trials. A 2008 randomized trial found no clinical effect on Alzheimer disease progression, and no supplied evidence shows that adding ipamorelin changes that finding or creates a proven benefit for body composition, recovery, sleep, or longevity. 3
Be cautious with claims built mainly on hormone biomarkers, individual stories, or prepackaged stack marketing. A licensed clinician can help separate a plausible biological idea from a treatment decision supported by useful human evidence.
MK-677 is a name used for ibutamoren mesylate. In the supplied human research, it is described as an orally active growth hormone secretagogue. 1
No supplied human study evaluates MK-677 combined with ipamorelin. Research on MK-677 alone cannot establish that the combination is effective or safe.
No. Growth hormone and IGF-1 are biomarkers. A change in a biomarker does not by itself prove better muscle mass, strength, recovery, daily function, or longer life. 4
Online stack marketing cannot replace an evaluation of your health history, medicines, goals, and possible risks. Do not use a product label or forum protocol as individualized medical guidance.
No compounded MK-677 or ipamorelin treatment is listed in Chia’s current offerings.
References
- 1.Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of Clinical Endocrinology and Metabolism. 1998.
- 2.Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of Gerontology and Geriatrics. 2011.
- 3.Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008.
- 4.ClinicalTrials.gov. Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients (NCT00395291). 2026.
- 5.ClinicalTrials.gov. Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults (NCT00474279). 2026.
- 6.ClinicalTrials.gov. Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects (NCT01343641). 2026.
- 7.ClinicalTrials.gov. Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency (NCT06948214). 2026.
- 8.ClinicalTrials.gov. Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients: completed registered study, 49 participants (NCT00395291). 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.



